peptides for FAQ

No peptide discussed here has been studied in breastfeeding populations with sufficient rigor to confirm safety. Thymalin and BPC-157 are not systemically absorbed in significant quantities (BPC-157 is a gastric peptide; Thymalin acts locally on thymic tissue), but transfer into breast milk has not been quantified. Collagen peptides are food-derived amino acid fragments with no known contraindication during lactation. Growth hormone secretagogues (ipamorelin, MK-677) elevate GH and IGF-1 systemically. Theoretical concern exists for infant exposure, though no case reports document harm. The conservative medical standard is to avoid peptides during breastfeeding unless the clinical benefit clearly outweighs unknown risk.

Yes, and most functional medicine protocols combine both. PPIs control acid exposure; peptides address tissue inflammation and repair. A patient on omeprazole 40mg daily can add BPC-157 250–500 mcg subcutaneously without pharmacological interaction. The mechanisms don't overlap. Monitor symptoms: if peptide therapy allows PPI dose reduction over 8–12 weeks, that suggests the tissue-level intervention is working.

Antimicrobial peptides like LL-37 target bacterial membranes, not archaeal cell walls. Methane-producing Methanobrevibacter smithii has a fundamentally different structure. Peptides are less likely to directly suppress methanogenic archaea, making them a poor monotherapy for IMO (intestinal methanogen overgrowth). However, barrier-restorative peptides like BPC-157 still address the intestinal permeability that coexists with methane SIBO, potentially reducing systemic inflammation and improving gut transit. Methane-dominant cases typically require neomycin or rifaximin plus neomycin combination therapy.

Stop using it immediately and check the formulation pH. Peptide serums below pH 4.0 or above pH 6.5 cause irritation in compromised rosacea skin. The ideal range is pH 4.5–5.5, matching the skin's natural acid mantle. If pH is correct, the stinging likely indicates barrier disruption severe enough that even well-tolerated actives penetrate too deeply. Switch to barrier repair only (ceramide-dominant moisturizer, colloidal oatmeal) for 2–4 weeks until tolerance improves, then reintroduce peptides at half the original concentration.

Antibody titre reduction is not the only meaningful outcome. Continue monitoring thyroid ultrasound findings, TSH/Free T4 stability, and symptom resolution (fatigue, brain fog, joint pain). Some patients show clinical improvement. Reduced thyroid inflammation on ultrasound, stabilised hormone requirements. Without significant antibody titre changes. The immune system's memory B cells can maintain antibody production even as active tissue destruction slows. Reassess at 16–20 weeks; if ultrasound shows progressive fibrosis or nodularity despite peptide intervention, the autoimmune process may require additional immunomodulatory strategies beyond peptide therapy alone.

Combining peptides with non-overlapping mechanisms. Such as thymalin for immune modulation plus BPC-157 for tissue repair. Is theoretically sound and commonly practiced in research settings. The risk lies in additive side effects (nausea, injection-site reactions) rather than direct drug interactions, since these peptides act on distinct receptor systems. Start one peptide at a time, establish tolerability over 2–4 weeks, then introduce the second compound. Never combine two immune-modulating peptides (thymalin + an experimental IL-2 analog, for example) without professional oversight. Overlapping pathways increase the risk of immune overactivation or paradoxical suppression.

Apply peptides at least five days per week to maintain therapeutic concentration in dermal tissue. Fibroblast signalling requires sustained peptide presence. Sporadic application (2–3 times weekly) doesn't maintain the receptor activation needed to upregulate collagen gene expression. Studies showing 20–35% wrinkle reduction used twice-daily protocols without interruption. If you miss application days, restart consistency immediately rather than increasing concentration to compensate.

No human safety data exists for BPC-157 in anorectal conditions specifically. Rodent toxicity studies at doses up to 1000 times therapeutic levels showed no adverse effects, and the small human case series in fissure healing reported no serious events. The primary risk isn't toxicity. It's contamination from improper reconstitution or injection technique. If you proceed with research-grade BPC-157, source it from a verified supplier with third-party purity testing (HPLC and mass spectrometry), use sterile bacteriostatic water for reconstitution, and follow aseptic technique for every injection.

No. TB-4's mechanism depends on sustained tissue-level concentrations, not peak dosing. If you miss a scheduled injection by fewer than 3 days, administer the dose and resume your normal schedule. If more than 3 days have passed, skip the missed dose and continue on your next scheduled date. Doubling doses does not accelerate angiogenesis. It increases the risk of localized immune modulation effects without added benefit.

Do not bypass evidence-based IC therapies (dietary modification, bladder instillations, pelvic floor physical therapy) in favour of investigational peptides. The research-grade peptides discussed here lack dosing protocols, safety profiles, and efficacy data in human IC patients. Attempting self-administration based on rodent study parameters introduces unpredictable risks. Standard IC treatments have known response rates, adverse event profiles, and clinical guidelines; research peptides have none of these. Our team at Real Peptides provides compounds exclusively for laboratory research under appropriate institutional oversight, not for unmonitored self-experimentation. Clinical decision-making for IC should prioritise treatments with established human evidence.

Request fecal calprotectin and serum zonulin testing to quantify ongoing inflammation and barrier dysfunction—standard antibody panels (tTG-IgA, DGP-IgG) may normalize while intestinal damage persists. If biomarkers confirm persistent permeability, peptides like BPC-157 or KPV theoretically target tight junction repair and inflammation that dietary elimination alone doesn't resolve. This is investigational—work with a physician experienced in peptide research protocols, and understand you're pursuing experimental adjunctive therapy outside standard care. Most gastroenterologists won't prescribe peptides because evidence for celiac-specific efficacy doesn't exist yet.

Lyophilized BPC-157, TB-500, and GHK-Cu must be stored at −20°C before reconstitution. Once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days for BPC-157 and GHK-Cu, or within 30 days for TB-500 based on stability data from peptide synthesis facilities. Any temperature excursion above 8°C risks protein denaturation that neither visual inspection nor at-home potency testing can detect. The peptide may look fine but lose biological activity entirely. For multi-week study protocols, prepare fresh aliquots rather than relying on a single large batch stored for extended periods. Our team has reviewed this across hundreds of research applications: storage protocol violations are the single most common source of inconsistent results in peptide-based vascular studies.

Chronic post-concussive symptoms (headaches, brain fog, mood changes persisting beyond 3 months) may respond to peptides targeting neuroinflammation or synaptic plasticity, though evidence is weaker than acute-phase interventions. P21's effects on long-term potentiation and dendritic spine density suggest potential for late-stage cognitive recovery, but no trials have tested this directly. Thymalin addresses prolonged microglial activation that contributes to persistent symptoms. Dosing follows the same 10mg daily protocol, though optimal treatment duration for chronic cases remains undefined.

Discard it immediately. Cloudiness indicates protein aggregation or bacterial contamination, both of which render the peptide ineffective and potentially harmful. Properly reconstituted BPC-157 and TB-500 should be completely clear with no visible particles. Cloudiness develops when peptides are reconstituted with non-bacteriostatic water, exposed to temperatures above 25°C, or contaminated during draw procedures. Temperature excursions are irreversible. Refrigerating a cloudy solution won't restore peptide integrity.

Check reconstitution and storage integrity first. BPC-157 is sensitive to temperature excursions above 8°C, and improperly stored solutions lose bioactivity without visible degradation. The peptide's angiogenic mechanism requires 48–72 hours to produce measurable VEGF upregulation, so functional outcomes before day 5 are uncommon. If administration timing, dosing accuracy, and storage conditions are confirmed correct, consider whether the injury model itself involves sufficient vascular disruption. Crush injuries with intact blood supply may not show the same BPC-157 responsiveness as transection models where angiogenesis is rate-limiting.

Begin with TB-500 to address chronic muscle dysfunction first. The initial inflammatory phase has passed, but satellite cell activation remains viable for 6–8 weeks post-injury. TB-500 can still recruit these progenitor cells to damaged muscle fibers. Pair it with BPC-157 to target any residual ligament laxity or tendon inflammation that persists beyond the acute phase. Research on delayed peptide administration shows reduced efficacy compared to immediate post-injury dosing, but meaningful improvements in tissue quality still occur when started within the first two months.

Continue the protocol through at least four weeks before evaluating efficacy. BPC-157 works by accelerating tissue repair, not by blocking pain receptors. Subjective pain reduction follows measurable tissue healing, which takes time. Animal studies showing accelerated tendon healing demonstrated the most significant structural improvements between weeks 2–4 of treatment. If pain persists beyond six weeks with no reduction in severity, the pain source may not be structural tissue damage (the mechanism BPC-157 addresses) but nerve sensitization or systemic inflammation requiring a different approach.

Avoid thymic peptides if you have active autoimmune disease. Thymalin enhances T-cell differentiation and immune surveillance, which can exacerbate autoimmune flares by amplifying the hyperactive immune response driving tissue damage. The mechanism that restores immune competence in immunosenescent elderly patients works against you when your immune system is already overactive. Consult an immunologist before considering any immune-modulating peptide if you have rheumatoid arthritis, lupus, Crohn's disease, or other autoimmune conditions.

Dihexa is the most promising compound for dual cognitive enhancement and neuroprotection, though human stroke data doesn't exist yet. Preclinical models show 30–40% increases in hippocampal synaptic density within weeks, and the compound protects neurons from excitotoxic death in ischemia models. Oral bioavailability is ~50%, making it practical for daily use at 5mg doses. The trade-off: you're using a compound with Phase I safety data but no Phase II efficacy trials in humans. That's an acceptable risk profile for research use but not yet a clinical recommendation.

Use separate vehicle controls for each peptide to account for solvent effects. Cerebrolysin requires saline, Dihexa uses DMSO or ethanol at low percentages, and P21 can be delivered intranasally in sterile water. Dose timing matters: neurotrophic peptides like Cerebrolysin require chronic administration (daily for 2–4 weeks), while Dihexa shows effects after single doses. Stagger your treatment groups to avoid confounding developmental timing with peptide effects.